Verastem, Inc. (VSTM) Bundle
Understanding Verastem, Inc. (VSTM) Revenue Streams
Understanding Verastem, Inc.’s Revenue Streams
Verastem, Inc. primarily generates revenue through the sale of licenses and related assets. As of September 30, 2024, the company recorded revenue of $10 million from the sale of the COPIKTRA license, marking a significant increase from $0 in the previous year. This milestone payment was tied to Secura achieving cumulative worldwide net sales of COPIKTRA exceeding $100 million during the 2024 period.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for Verastem can be summarized as follows:
| Year | Revenue ($ millions) | Year-over-Year Growth (%) |
|---|---|---|
| 2023 | $0 | 0% |
| 2024 | $10 | 100% |
Contribution of Different Business Segments to Overall Revenue
The total revenue for the nine months ended September 30, 2024, was entirely attributed to the sale of the COPIKTRA license. No additional revenue was reported from other segments, as the company has transitioned away from direct product sales following the licensing agreement.
Analysis of Significant Changes in Revenue Streams
In the prior year, Verastem reported no revenue, as it had already sold its COPIKTRA license and was not generating revenue from product sales. The significant shift in revenue for 2024 is attributed to the successful milestone payment of $10 million related to the COPIKTRA license. This change highlights the company's strategic focus on licensing agreements rather than direct sales.
The following table provides a comparison of revenue sources for the current and previous years:
| Revenue Source | 2023 ($ million) | 2024 ($ million) |
|---|---|---|
| Sale of COPIKTRA License | $0 | $10 |
| Other Revenue | $0 | $0 |
A Deep Dive into Verastem, Inc. (VSTM) Profitability
A Deep Dive into Verastem, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported a total revenue of $10 million from the sale of COPIKTRA license and related assets. The gross profit margin is calculated as revenue minus cost of goods sold (COGS). However, specific COGS data was not provided, indicating a focus on net revenue rather than gross profit metrics for this period.
Operating Profit Margin: The total operating expenses for the nine months ended September 30, 2024, were $93.4 million, resulting in a loss from operations of $(83.4 million). This reflects an increase in operating expenses of 53% compared to the previous year.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $(66.1 million), which translates to a net profit margin of -660% based on the total revenue of $10 million.
Trends in Profitability Over Time
Comparing the nine months ended September 30, 2024, to the same period in 2023, the company’s net loss increased by 10% from $(60 million) to $(66.1 million). This indicates an ongoing trend of increasing losses despite generating revenue.
Comparison of Profitability Ratios with Industry Averages
While specific industry averages were not detailed in the available data, the company’s net profit margin of -660% and operating profit margin of -837% can be compared with industry peers in the biotechnology sector, which typically experience negative margins during early commercialization phases.
Analysis of Operational Efficiency
Cost Management: The increase in operating expenses to $93.4 million was driven primarily by a rise in research and development expenses, which totaled $60.5 million, indicating a focus on product development. The company also incurred $32.8 million in selling, general, and administrative expenses, reflecting a 49% increase from the previous year.
| Metric | 2024 (Nine Months) | 2023 (Nine Months) | Change (%) |
|---|---|---|---|
| Total Revenue | $10 million | $0 million | 100% |
| Total Operating Expenses | $93.4 million | $60.9 million | 53% |
| Net Loss | $(66.1 million) | $(60 million) | 10% |
| Research and Development Expenses | $60.5 million | $38.9 million | 56% |
| Selling, General and Administrative Expenses | $32.8 million | $22.1 million | 49% |
Gross Margin Trends: The company’s focus on increasing its revenue through licensing agreements is evident, but the lack of profitability metrics indicates challenges in achieving sustainable gross margins.
Debt vs. Equity: How Verastem, Inc. (VSTM) Finances Its Growth
Debt vs. Equity Structure
As of September 30, 2024, the company reported a total long-term debt of $40.5 million. This includes a principal loan balance of $40 million and a final payment fee of $1.0 million. The current portion of long-term debt stands at $9.9 million, while the long-term debt, net of the current portion, is $30.6 million.
The debt-to-equity ratio is a critical measure of financial leverage. For the company, the debt-to-equity ratio is approximately 3.67, calculated from total liabilities of $126.4 million and total stockholders' equity of $11.1 million. This ratio indicates a higher reliance on debt financing compared to equity, suggesting potential risks associated with high leverage.
In recent financing activity, the company completed a public offering on July 23, 2024, which raised approximately $50.8 million in net proceeds. This offering included the sale of 13.3 million shares of common stock and accompanying warrants. The company also has a loan agreement with Oxford, which was amended in March 2022, allowing for additional debt drawdowns.
The company maintains a balance between debt financing and equity funding by utilizing various sources of capital. As of September 30, 2024, cash, cash equivalents, and investments totaled $113.2 million, providing a liquidity cushion for operational needs. The financing strategy includes public offerings, private investments, and collaborations, ensuring the company can support its growth initiatives while managing its debt levels effectively.
| Financial Metric | Amount |
|---|---|
| Total Long-term Debt | $40.5 million |
| Principal Loan Balance | $40 million |
| Final Payment Fee | $1 million |
| Current Portion of Long-term Debt | $9.9 million |
| Long-term Debt (Net of Current Portion) | $30.6 million |
| Debt-to-Equity Ratio | 3.67 |
| Cash, Cash Equivalents, and Investments | $113.2 million |
| Net Proceeds from July 2024 Offering | $50.8 million |
Assessing Verastem, Inc. (VSTM) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio, which measures the company's ability to cover its short-term liabilities with its short-term assets, stood at 3.22 as of September 30, 2024. The quick ratio, a more stringent measure that excludes inventory from current assets, was 3.22 as well, indicating a strong liquidity position.
Analysis of Working Capital Trends
As of September 30, 2024, the working capital was calculated as follows:
| Current Assets | Current Liabilities | Working Capital |
|---|---|---|
| $120,662,000 | $37,374,000 | $83,288,000 |
This reflects a working capital increase compared to the previous year, where the working capital was $117,302,000 as of December 31, 2023. The increase in working capital indicates improved liquidity and operational efficiency.
Cash Flow Statements Overview
The cash flow from operating, investing, and financing activities for the nine months ending September 30, 2024, is outlined below:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(79,672) | $(56,779) |
| Net cash provided by investing activities | $59,972 | $(56,883) |
| Net cash provided by financing activities | $54,040 | $134,640 |
Overall, the net cash used in operating activities reflects ongoing operational costs, while the positive cash flow from investing and financing activities indicates a strategic approach to funding operations.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported cash, cash equivalents, and investments amounting to $113.2 million. However, there are liquidity concerns highlighted by the accumulated deficit of $891 million. This raises questions regarding the sustainability of operations without additional financing, as net losses were reported at $66.1 million for the nine months ended September 30, 2024.
The company faces substantial doubt regarding its ability to continue as a going concern, given the anticipated ongoing operating losses and the need for further capital raising to support operational and development activities.
Is Verastem, Inc. (VSTM) Overvalued or Undervalued?
Valuation Analysis
The valuation of a company provides insights into whether it is overvalued or undervalued based on various financial metrics. For the analysis of Verastem, Inc. (VSTM), we will examine key ratios, stock price trends, dividend metrics, and analyst consensus.
Price-to-Earnings (P/E) Ratio
As of the latest financial reports, the price-to-earnings (P/E) ratio for Verastem, Inc. is –. A negative P/E indicates that the company is currently not generating profits. This metric is crucial for assessing the relative value of the company's shares compared to its earnings.
Price-to-Book (P/B) Ratio
The price-to-book (P/B) ratio for Verastem, Inc. stands at –. This ratio helps investors determine if the stock is undervalued or overvalued relative to its book value. A P/B ratio under 1 can indicate that the stock is undervalued.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value-to-EBITDA (EV/EBITDA) ratio is currently –. This metric is essential for valuing the company in relation to its earnings before interest, taxes, depreciation, and amortization, providing a clearer picture of operational performance compared to net income.
Stock Price Trends
Over the past 12 months, the stock price of Verastem, Inc. has experienced fluctuations. The stock opened at $– and closed at $–, reflecting a percentage change of –% over the period. Key milestones include:
- Highest price: $–
- Lowest price: $–
Dividend Yield and Payout Ratios
Verastem, Inc. does not currently offer dividends, leading to a dividend yield of 0%. The absence of dividends may indicate that the company is reinvesting its earnings into growth opportunities rather than returning capital to shareholders.
Analyst Consensus on Stock Valuation
Analyst consensus on Verastem, Inc. indicates a rating of –, suggesting a sentiment of buy, hold, or sell based on current valuations and market conditions. This consensus is based on recent performance, growth potential, and market dynamics.
| Metric | Value |
|---|---|
| P/E Ratio | – |
| P/B Ratio | – |
| EV/EBITDA Ratio | – |
| 12-Month Stock Price Change | –% |
| Dividend Yield | 0% |
| Analyst Consensus | – |
Key Risks Facing Verastem, Inc. (VSTM)
Key Risks Facing Verastem, Inc.
Verastem, Inc. faces a variety of internal and external risks that may impact its financial health. These risks include industry competition, regulatory changes, and evolving market conditions that can affect the company’s strategic operations and financial performance.
Industry Competition
The biopharmaceutical industry is characterized by intense competition. As of September 30, 2024, Verastem had an accumulated deficit of $891.0 million. The company competes with established pharmaceutical firms that have more resources for research and development, which can limit Verastem's market share and pricing power.
Regulatory Changes
Changes in regulatory requirements can significantly affect the company’s ability to develop and market its products. The company has not yet received regulatory approval for its product candidates, which adds uncertainty to its future revenue streams.
Market Conditions
Market conditions, including shifts in healthcare policies and funding for research, can impact Verastem’s operational capabilities. The company's revenue from the sale of the COPIKTRA license and related assets was $10.0 million for the nine months ended September 30, 2024, compared to $0.0 million for the same period in 2023, indicating potential volatility in revenue generation.
Operational Risks
Operational risks include reliance on contract research organizations (CROs) and contract manufacturers. There may be fluctuations in foreign currency rates impacting contracts denominated in currencies other than the functional currency. As of September 30, 2024, the company had borrowed $40.0 million under its Loan Agreement.
Financial Risks
Financial risks stem from the company’s ongoing operating losses. For the three months ended September 30, 2024, Verastem reported a net loss of $23.97 million, which increased from $20.00 million in the previous year. The company’s total liabilities were $94.16 million as of September 30, 2024.
Strategic Risks
Strategic risks include the potential failure to establish new collaborations or partnerships, which are crucial for obtaining financing and facilitating product development. The company has faced challenges in attracting and retaining high-quality personnel necessary for its operational success.
Mitigation Strategies
Verastem has outlined several strategies to mitigate these risks, including diversifying its funding sources and pursuing partnerships to enhance its product pipeline. The company aims to finance its operations through future milestones and royalties received pursuant to the asset purchase agreement.
| Risk Type | Description | Impact |
|---|---|---|
| Industry Competition | Intense competition from larger pharmaceutical companies. | Limits market share and pricing power. |
| Regulatory Changes | Potential changes in regulations affecting product approval. | Uncertainty in future revenue streams. |
| Market Conditions | Shifts in healthcare policies and funding for research. | Volatility in revenue generation. |
| Operational Risks | Reliance on CROs and foreign currency fluctuations. | Increased operational costs. |
| Financial Risks | Ongoing operating losses and high liabilities. | Pressure on cash flow and financial stability. |
| Strategic Risks | Challenges in establishing collaborations. | Reduced ability to secure financing. |
Future Growth Prospects for Verastem, Inc. (VSTM)
Future Growth Prospects for Verastem, Inc.
Analysis of Key Growth Drivers
Verastem's growth opportunities are significantly influenced by its product innovations and strategic initiatives. The company is currently focusing on the development of its lead product candidates, primarily avutometinib and defactinib, which are being evaluated in multiple clinical trials for treating various cancers.
In particular, the RAMP 203 study, which has included defactinib, has seen substantial increases in associated costs, reflecting the company's commitment to advancing its pipeline. The direct research and development expenses for the product candidates have notably increased:
| Product/Project | 2024 Costs (in thousands) | 2023 Costs (in thousands) | Change (in thousands) |
|---|---|---|---|
| Avutometinib + defactinib | $32,434 | $15,216 | $17,218 |
| Avutometinib + other combinations | $3,700 | $3,618 | $82 |
| GenFleet | $3,704 | $2,051 | $1,653 |
| Total R&D Expense | $60,523 | $38,854 | $21,669 |
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, Verastem reported a total revenue of $10 million from the sale of the COPIKTRA license, marking a 100% increase compared to the previous year when the revenue was $0.
Projected revenues from ongoing clinical trials and potential market launches of its product candidates could significantly enhance future earnings. Analysts anticipate continued investment in R&D, which is expected to drive long-term revenue growth as the company approaches potential product approvals.
Strategic Initiatives and Partnerships
Verastem is focused on establishing strategic collaborations to enhance its market position. The recent partnership with Secura Bio, under which the company received a $10 million milestone payment, reinforces this strategy. Such collaborations are expected to provide additional funding and resources necessary for the development of its product pipeline.
Competitive Advantages
Verastem's competitive advantages include a robust clinical pipeline and a strategic focus on oncology. The company has established a strong R&D platform, allowing it to leverage its expertise in developing innovative therapies. The increase in research and development expenses to $60.5 million for the nine months ended September 30, 2024, signifies a commitment to advancing its leading-edge treatment options.
Additionally, the company has maintained a strong liquidity position, reporting $113.2 million in cash and cash equivalents as of September 30, 2024, which supports ongoing operational and strategic initiatives.
Conclusion
The company's strategic focus on innovative product development, coupled with strong financial backing and strategic partnerships, positions it well for future growth in the competitive oncology market.
Verastem, Inc. (VSTM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Verastem, Inc. (VSTM) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Verastem, Inc. (VSTM)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Verastem, Inc. (VSTM)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.